Cyclerion Therapeutics (CYCN) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to 0.92.
- Cyclerion Therapeutics' Equity Ratio fell 60.09% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year decrease of 60.09%. This contributed to the annual value of 0.92 for FY2024, which is 950.87% up from last year.
- Cyclerion Therapeutics' Equity Ratio amounted to 0.92 in Q3 2025, which was down 60.09% from 0.91 recorded in Q2 2025.
- Cyclerion Therapeutics' 5-year Equity Ratio high stood at 0.92 for Q4 2024, and its period low was 0.34 during Q1 2023.
- For the 5-year period, Cyclerion Therapeutics' Equity Ratio averaged around 0.77, with its median value being 0.84 (2023).
- In the last 5 years, Cyclerion Therapeutics' Equity Ratio plummeted by 5695.8% in 2023 and then skyrocketed by 15486.2% in 2024.
- Over the past 5 years, Cyclerion Therapeutics' Equity Ratio (Quarter) stood at 0.81 in 2021, then decreased by 28.9% to 0.58 in 2022, then soared by 45.99% to 0.84 in 2023, then grew by 9.51% to 0.92 in 2024, then fell by 0.92% to 0.92 in 2025.
- Its Equity Ratio was 0.92 in Q3 2025, compared to 0.91 in Q2 2025 and 0.89 in Q1 2025.